Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale

Aclaris Therapeutics, Inc.

2024-Q2 EPS reported -$0.39 revenue$5,163,000

Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.
Cash, equivalents and securities $149.9M; July 2024 received $26.5M upfront from OLUMIANT royalty sale.
Phase 2a trial of ATI-2138 in atopic dermatitis initiated; enrollment expected in coming weeks.
Seeking global partner for lepzacitinib (ATI-1777) after positive Phase 2b top-line results.
R&D expense fell 65% to $8.8M due to completion of several clinical trials and headcount reductions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.